학술논문
Two-year visual and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
Document Type
article
Author
Takao Hirano; Yuichi Toriyama; Tatsuro Ishibashi; Taiji Sakamoto; Tomoaki Murakami; Nahoko Ogata; Yuichiro Ogura; Masahiko Shimura; Shigehiko Kitano; Yoshihiro Takamura; Jiro Kogo; Yoshinori Mitamura; Fumiki Okamoto; Masahiko Sugimoto; Sentaro Kusuhara; Hitoshi Takagi; Masaru Takeuchi; Akito Hirakata; Hidetoshi Yamashita; Katsuhiro Nishi; Keijiro Ishikawa; Masahito Ohji; Osamu Sawada; Shigeo Yoshida; Toshio Hisatomi; Miho Nozaki; Hideyasu Oh; Makoto Suzaki; Kimie Mori; Masanari Kozawa; Poh Sin Yap; Takeumi Kaneko; Hiroko Imaizumi; Sachi Abe
Source
BMJ Open Ophthalmology, Vol 7, Iss 1 (2022)
Subject
Language
English
ISSN
2397-3269
Abstract
Objective We report the 2-year visual and psychological outcomes of the MERCURY study, examining the long-term effectiveness and safety of ranibizumab and subsequent therapy in Japanese patients with diabetic macular oedema with impaired visual acuity (VA) in the real-world setting.Methods and analysis This was a 24-month, phase 4, open-label, single-arm, multicentre, prospective, observational study. Following an initial dose of ranibizumab (0.5 mg) by intravitreal injection (0.05 mL), treatment was administered as needed after month 1. The primary treated eye (PTE) was the first eye that received a ranibizumab injection.Results In total, 209 patients were enrolled; 192 (91.9%) and 174 (83.3%) completed months 12 and 24, respectively. In the PTE set, mean±SD changes in best-corrected VA (BCVA) from baseline to months 12 (primary endpoint) and 24 were −0.08±0.35 (p=0.015) and −0.13±0.30 (p